Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment University of Antwerp
The present invention relates to the field of combination immunotherapy, more in particular to a combination comprising IL-15 and a CD40 agonist for use in the treatment of cancer, such as and not limited to, melanoma skin cancer (e.g. : superficial spreading melanoma, nodular melanoma, acral-lentiginous melanoma, lentigo maligna melanoma, amelanotic and desmoplastic melanomas, ocular melanoma, and metastatic melanoma).